Elizabeth Hexner is a Hematology physician affiliated with University of Pennsylvania. OpenAlex indexes 481 publications with 15,072 citations (h-index 57); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
15 Penn Tower
Philadelphia, PA 19104
Telephone
215-662-3914Registry record last updated 21 Feb 2011.
Clinical trials
- Umbilical Cord Blood Transplant for Hematological Malignancies
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Blueprint Medicines CorporationProgram year20251 payment
- Blueprint Medicines CorporationProgram year20242 payments
- National Marrow Donor ProgramProgram year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
77.2%Kinase inhibitor52.7%Jakafi70%Ayvakit26%Sprycel5%Part D<11 patientsAntimetabolite19.5%Hydroxyurea100%Part D≥28 patients+ 1 more class in this area
Metabolism & gastrointestinal
6.8%H2 blocker6.8%Famotidine100%Part D<11 patientsRespiratory
4.6%Mast Cell Stabilizer2.6%Cromolyn Sodium100%Part D<11 patientsHistamine-1 Receptor Antagonist2%Cetirizine Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2009–2026 per NIH RePORTER. The latest:
- CTSA Postdoctoral T32 at the University of Pennsylvania
University of Pennsylvania
FY2026$532,701T32TR006158 - The cell and gene therapy toolkit for junior faculty
University of Pennsylvania
FY2022$338,745UE5CA246744 - The cell and gene therapy toolkit for junior faculty
University of Pennsylvania
FY2021$338,745UE5CA246744
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Harold Feldman, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”